Andrea Lobo,  —

Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize the oral treatment IPX203 for Parkinson’s disease in the European Union, U.K., and Switzerland. IPX203 is an experimental extended-release formulation of carbidopa and levodopa, designed to ease…

A metabolite called M324 of the cancer medicine rucaparib is able to reduce the abnormal accumulation of alpha-synuclein protein in nerve cells derived from people with Parkinson’s disease, showing its potential for treating the neurodegenerative disorder, according to a new study. Metabolites are molecules that result from the biochemical…

The Swiss company Vandria has been awarded a multimillion-dollar research grant to help advance the development of VNA-318, its therapy candidate for age-related neurological conditions, including Parkinson’s disease. Totaling 2.5 million Swiss francs (about $2.8 million), the grant is funded by the Swiss Innovation Agency Innosuisse, which provides…

Long-term practice of the Chinese martial art tai chi for Parkinson’s disease was shown to ease nonmotor symptoms among patients in a yearlong trial in China. Specifically, improved cognition was seen among people with the neurodegenerative disease after one year of the exercise program, according to study data. Conversely, at…

The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…

Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…

Knight Therapeutics has entered into an exclusive license agreement with Amneal Pharmaceuticals giving it rights to apply for  regulatory approval of IPX203 in Canada and across Latin America, and, if granted, to market the Parkinson’s disease treatment there. IPX203 is an investigational, extended-release oral formulation…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…

Centogene and The Michael J. Fox Foundation (MJFF) are teaming up on a research project to investigate genetic risk factors for Parkinson’s disease, with a particular focus on GBA gene mutations. This project’s main goal is to better understand how certain variations in the GBA gene are connected…

A new brain imaging method may help diagnose mild traumatic brain injury (mTBI), which according to some studies can be associated with a 50% higher risk of developing Parkinson’s. Available methods, like magnetic resonance imaging (MRI), leave most cases of mTBI, or concussions, undiagnosed. They occur when a physical…